Every day, more than 1,000 people worldwide will be diagnosed with pancreatic cancer.
The number of new cases per year is still increasing and should reach 418,451 new cases in 2020, amongst them 142,000 in Europe+USA (source: IARC/Globocan). Pancreatic cancer is now the third leading cause of cancer-related death in the United States, and it is anticipated to become the second around 2020 (source: Pancan & American Cancer Society Cancer Facts & Figures 2018).
After years of silent progression, 80% of patients diagnosed with pancreatic cancer have unresectable tumors. For those people, chemotherapy is the only first therapeutic option. The Gemcitabine treatment in pancreatic cancer is generally associated with a 6.7-month survival.
Acobiom discovered and patented a combination of blood RNA-biomarkers that is correlated to the prediction of a 14.9-month survival for a sub-population of patients diagnosed with Pancreatic Cancer and treated by Gemcitabine.
Based on this Blood RNA-biomarker signature, Acobiom developed a new In-Vitro Diagnostic, called GemciTest. This IVD can be used on the LC480 qRT-PCR platform.
Hence, this Blood Diagnostic Test can identify the patients suffered from pancreatic cancer that are the most likely to benefit from gemcitabine.
To illustrate the overall survival benefits of the GemciTest, the sub-population of patients identified by the GemciTest is characterized by the following rates:
> 65% of them are alive 12 months after the diagnostic of the disease (versus 35%* for the patients treated by the combination Abraxane+Gemcitabine and 24% for the patients treated blindly by gemcitabine),
> 50% of them are alive 14.9 months after the diagnostic of the disease (versus 20%* for the patients treated by the combination Abraxane+Gemcitabine and 11% for the patients treated blindly by gemcitabine).
The Cancer hospital (CGFL) of Dijon (France) is currently evaluating in a 2-year clinical study the prognostic value of the GemciTest on every patients diagnosed with pancreatic cancer and treated by chemotherapy. The Chief Investigator for this study is Professor François Ghiringhelli, Centre de Lutte Contre le Cancer (CGFL, Dijon, France).
To confirm GemciTest’s benefits, Acobiom signed also a partnership in 2018 with the Toulouse Hospital (France) to have access to the BACAP clinical & biological database, containing clinical and epidemiological data, as well as associated biological samples, collected from 1,500 pancreatic cancer patients recruited by the 15 clinical centers, partners of the BACAP program (see press release).
Moreover, Acobiom established a collaborative agreement with the University of Wisconsin’s Carbone Cancer Center (UWCCC, Madison, Wisconsin, USA) to develop Precision Medicine approach in the field of pancreatic adenocarcinoma treatment. This partnership is also a prerequisite before commercializing GemciTest® on US market (see press release).
The SOP of the GemciTest is available for routine analyses and the diagnostic can be ordered for « Research Use Only » (RUO).
The benefits of the GemciTest on clinical and economical aspects are described in the following document: The GemciTest flyer.
If you need more information, please contact our business development department (T: +33(0)467 419 748, Email: email@example.com).